WO2008040774A3 - Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats - Google Patents

Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats Download PDF

Info

Publication number
WO2008040774A3
WO2008040774A3 PCT/EP2007/060531 EP2007060531W WO2008040774A3 WO 2008040774 A3 WO2008040774 A3 WO 2008040774A3 EP 2007060531 W EP2007060531 W EP 2007060531W WO 2008040774 A3 WO2008040774 A3 WO 2008040774A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
angiotensin
cats
systemic diseases
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/060531
Other languages
French (fr)
Other versions
WO2008040774A2 (en
Inventor
Marcus Stark
Ulrike Sent
Ingo Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008040774(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2009530883A priority Critical patent/JP5425631B2/en
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Priority to CN2007800374949A priority patent/CN101522191B/en
Priority to CN202111463480.1A priority patent/CN114344293B/en
Priority to EP07820908.7A priority patent/EP2086535B1/en
Priority to KR1020097009113A priority patent/KR101456151B1/en
Priority to DK07820908.7T priority patent/DK2086535T3/en
Priority to AU2007304216A priority patent/AU2007304216B9/en
Priority to PL07820908T priority patent/PL2086535T3/en
Priority to HRP20130696TT priority patent/HRP20130696T1/en
Priority to MX2013004347A priority patent/MX360148B/en
Priority to NZ576109A priority patent/NZ576109A/en
Priority to MX2013004349A priority patent/MX360150B/en
Priority to MX2013004348A priority patent/MX360147B/en
Priority to CA2665435A priority patent/CA2665435C/en
Priority to ES07820908T priority patent/ES2425482T3/en
Priority to KR1020147014825A priority patent/KR101529541B1/en
Priority to MX2009002340A priority patent/MX2009002340A/en
Priority to BRPI0718041 priority patent/BRPI0718041A2/en
Priority to SI200731289T priority patent/SI2086535T1/en
Publication of WO2008040774A2 publication Critical patent/WO2008040774A2/en
Publication of WO2008040774A3 publication Critical patent/WO2008040774A3/en
Anticipated expiration legal-status Critical
Priority to CY2013037C priority patent/CY2013037I1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of prophylaxis or treatment of systemic diseases in cats, wherein the method comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.
PCT/EP2007/060531 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats Ceased WO2008040774A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SI200731289T SI2086535T1 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
MX2013004349A MX360150B (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats.
CN2007800374949A CN101522191B (en) 2006-10-06 2007-10-04 Angiotensin II Receptor Antagonists for Systemic Diseases in Felines
CN202111463480.1A CN114344293B (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonists for the treatment of systemic disease in cats
EP07820908.7A EP2086535B1 (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
KR1020097009113A KR101456151B1 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
DK07820908.7T DK2086535T3 (en) 2006-10-06 2007-10-04 Angiotension II receptor antagonist for the treatment of systemic diseases in cats
AU2007304216A AU2007304216B9 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
PL07820908T PL2086535T3 (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
HRP20130696TT HRP20130696T1 (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
MX2013004347A MX360148B (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats.
JP2009530883A JP5425631B2 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
CA2665435A CA2665435C (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
NZ576109A NZ576109A (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
MX2013004348A MX360147B (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats.
ES07820908T ES2425482T3 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
KR1020147014825A KR101529541B1 (en) 2006-10-06 2007-10-04 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
MX2009002340A MX2009002340A (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats.
BRPI0718041 BRPI0718041A2 (en) 2006-10-06 2007-10-04 Angiotensin II Receptor Antagonist for the Prevention or Treatment of Systemic Diseases in Cats
CY2013037C CY2013037I1 (en) 2006-10-06 2013-09-18 ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF SYSTEMIC DISEASE IN CATS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121905A EP1908469A1 (en) 2006-10-06 2006-10-06 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP06121905.1 2006-10-06

Publications (2)

Publication Number Publication Date
WO2008040774A2 WO2008040774A2 (en) 2008-04-10
WO2008040774A3 true WO2008040774A3 (en) 2008-07-10

Family

ID=37744125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/060531 Ceased WO2008040774A2 (en) 2006-10-06 2007-10-04 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats

Country Status (25)

Country Link
US (5) US8772278B2 (en)
EP (5) EP1908469A1 (en)
JP (5) JP5425631B2 (en)
KR (2) KR101456151B1 (en)
CN (6) CN101522191B (en)
AR (1) AR063155A1 (en)
BR (4) BRPI0718041A2 (en)
CA (1) CA2665435C (en)
CL (2) CL2007002897A1 (en)
CO (1) CO6180425A2 (en)
CY (2) CY1114266T1 (en)
DK (4) DK2420232T3 (en)
ES (4) ES2567041T3 (en)
HR (1) HRP20130696T1 (en)
HU (4) HUE027280T2 (en)
LU (1) LU92282I2 (en)
MX (4) MX2009002340A (en)
NL (1) NL300616I2 (en)
NZ (3) NZ609533A (en)
PL (4) PL2420232T3 (en)
PT (1) PT2086535E (en)
SI (1) SI2086535T1 (en)
TW (3) TWI415605B (en)
WO (1) WO2008040774A2 (en)
ZA (1) ZA200901218B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AR068814A1 (en) * 2007-08-29 2009-12-09 Orion Corp PHARMACEUTICAL COMPOSITION INCLUDING LEVOSIMENDAN AND AN INHIBITOR OF THE CONVERSINE ENZYME OF ANGIOTENSIN (ACE), AND USE
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
SG176585A1 (en) 2009-05-20 2012-01-30 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution
CN102283832B (en) * 2011-09-09 2013-04-10 南京正宽医药科技有限公司 Medicinal composition for preventing or treating hypertensive obese patient and application thereof
US9808529B2 (en) * 2012-05-18 2017-11-07 Luoda Pharma Pty Ltd Liquid formulation
DE102012018903A1 (en) 2012-09-26 2014-03-27 Elisabeth Kurth Breast bell for manual lactation of milk from the female breast
CN105233288A (en) * 2015-09-28 2016-01-13 青岛云天生物技术有限公司 Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension
JP6800633B2 (en) * 2016-07-04 2020-12-16 株式会社カネカ How to control the decline in renal function in non-human animals
AU2018295387B2 (en) * 2017-07-07 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
EP3996709A1 (en) * 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
US20240058309A1 (en) * 2020-12-28 2024-02-22 Cured Inc. Pharmaceutical composition for treating chronic kidney disease
KR20260019532A (en) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 Combination treatment and/or prevention of renal disease and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078699A2 (en) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Kg Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (en) 1953-07-10 1958-01-23 Hoffmann La Roche Process for the production of polyenedialdehydes
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122010000024I1 (en) 1990-02-19 2010-07-08 Novartis Ag acyl compounds
PT97078B (en) 1990-03-20 1997-07-31 Sanofi Sa PROCESS FOR THE PREPARATION OF N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
SI9210098B (en) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
EP0636027B1 (en) 1992-04-13 1999-07-07 Zeneca Limited Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
JP3862295B2 (en) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 Anti-obesity agent
JP3883205B2 (en) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド Treatment of Atherosclerosis with Angiotensin II Receptor Blocking Imidazole
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
ATE216881T1 (en) * 1996-06-24 2002-05-15 Merck & Co Inc COMPOSITION BASED ON ENALAPRIL AND LOSARTAN
ES2214013T3 (en) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd PREPARATION OF SUSTAINED RELEASE FOR AN ANTAGONIST OF AII, ITS PRODUCTION AND USE.
JPH11315034A (en) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd Sustained release preparation of compound having angiotensin ii antagonism, its production and use
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (en) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP2005501815A (en) 2001-05-14 2005-01-20 メルク　エンド　カムパニー　インコーポレーテッド Method of treatment
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE10153737A1 (en) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
WO2003097099A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1578360A4 (en) * 2002-08-28 2009-10-21 Curis Inc SIMULTANEOUS ADMINISTRATION OF MORPHOGENIC AND ACE INHIBITORS IN THE TREATMENT OF CHRONIC KIDNEY INUFFICIENCY
DE10244681A1 (en) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh New solid telmisartan-containing pharmaceutical formulations and their preparation
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (en) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Multilayer tablet
WO2005123070A1 (en) * 2004-06-09 2005-12-29 Fibrogen, Inc. Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN1602960A (en) * 2004-07-23 2005-04-06 海南国栋药物研究所有限公司 Mixture for preventing and treating metabolic syndrome like cerebrovascular and cardiovascular disease
CN100364532C (en) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 Composition containing amlodipine and angiotensin II receptor inhibitor
RS53141B (en) * 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh TWO-LAYER TABLE CONTAINING TELMISARTAN AND AMLODIPINE
CN1813707A (en) * 2004-12-01 2006-08-09 鲁南制药集团股份有限公司 Pharmaceutical composition containing isosorbide mononitrate for treating hypertension
US20070026026A1 (en) 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
SG176585A1 (en) 2009-05-20 2012-01-30 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078699A2 (en) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Kg Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ASIEDU-GYEKYE I J ET AL: "Does Losartan prevent cerebral edema? A preliminary study using a vascular compartment model", MEDICAL SCIENCE MONITOR, MEDISCIENCE PUBLIKACJE NAUKOWE, WARZAW, PL, vol. 9, no. 3, March 2003 (2003-03-01), pages BR127 - BR130, XP002311102, ISSN: 1234-1010 *
CHAMPION HUNTER C ET AL: "Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. SUPPL. 11, January 1999 (1999-01-01), pages S101 - S103, XP008075569, ISSN: 1046-6673 *
CINGOLANI HORACIO E ET AL: "The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species.", HYPERTENSION APR 2006, vol. 47, no. 4, April 2006 (2006-04-01), pages 727 - 734, XP008075568, ISSN: 1524-4563 *
GARRISON E A ET AL: "[Pro<11>,D-Ala<12>]angiotensin I has rapid onset vasoconstrictor activity in the cat", AMERICAN JOURNAL OF PHYSIOLOGY - ENDOCRINOLOGY AND METABOLISM 1997 UNITED STATES, vol. 273, no. 6 36-6, 1997, pages E1059 - E1064, XP008075565, ISSN: 0193-1849 *
KUMARI R ET AL: "Effect of Pre- and Posttreatment of Losartan in Feline Model of Myocardial Ischemic-Reperfusion Injury", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 2004 SPAIN, vol. 26, no. 1, 2004, pages 39 - 45, XP008075575, ISSN: 0379-0355 *
MATHUR S ET AL: "Evaluation of a technique of inducing hypertensive renal insufficiency in cats", AMERICAN JOURNAL OF VETERINARY RESEARCH 2004 UNITED STATES, vol. 65, no. 7, 2004, pages 1006 - 1013, XP008075574, ISSN: 0002-9645 *
STEBBINS CHARLES L ET AL: "Spinal angiotensin II influences reflex cardiovascular responses to muscle contraction", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 269, no. 4 PART 2, 1995, pages R864 - R868, XP008075571, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
JP6337170B2 (en) 2018-06-06
CN102580095A (en) 2012-07-18
PL2420231T3 (en) 2016-07-29
MX360148B (en) 2018-10-24
JP6151123B2 (en) 2017-06-21
US20080146543A1 (en) 2008-06-19
US20180193317A1 (en) 2018-07-12
CN102580095B (en) 2015-12-09
LU92282I2 (en) 2013-11-19
HUE027280T2 (en) 2016-09-28
US9308197B2 (en) 2016-04-12
ES2562182T3 (en) 2016-03-02
US8772278B2 (en) 2014-07-08
CN109125730A (en) 2019-01-04
LU92282I9 (en) 2019-01-17
CY2013037I2 (en) 2015-11-04
US20140288138A1 (en) 2014-09-25
JP2017122115A (en) 2017-07-13
HUS1300062I1 (en) 2013-11-28
KR101529541B1 (en) 2015-06-17
WO2008040774A2 (en) 2008-04-10
NL300616I2 (en) 2016-06-01
KR20090080954A (en) 2009-07-27
CN105148272A (en) 2015-12-16
AU2007304216A1 (en) 2008-04-10
HRP20130696T1 (en) 2013-09-30
TWI539950B (en) 2016-07-01
CN114344293B (en) 2024-04-19
NZ597648A (en) 2013-05-31
MX2009002340A (en) 2009-03-23
JP2016094436A (en) 2016-05-26
EP2420232B1 (en) 2016-01-06
ZA200901218B (en) 2010-03-31
US9949954B2 (en) 2018-04-24
HUS1800044I1 (en) 2018-12-28
AR063155A1 (en) 2008-12-30
KR20140088601A (en) 2014-07-10
BR122013019535A2 (en) 2015-07-14
PL2086535T3 (en) 2013-10-31
ES2565519T3 (en) 2016-04-05
PL2420233T3 (en) 2016-07-29
JP2013216709A (en) 2013-10-24
CY1114266T1 (en) 2015-11-04
TW201332547A (en) 2013-08-16
EP2086535A2 (en) 2009-08-12
TW201402115A (en) 2014-01-16
CN101522191B (en) 2012-05-16
EP2420233A3 (en) 2012-04-18
AU2007304216B2 (en) 2013-06-13
NZ576109A (en) 2012-02-24
PL2420232T3 (en) 2016-06-30
DK2420233T3 (en) 2016-04-11
EP2086535B1 (en) 2013-05-22
CN102512678A (en) 2012-06-27
JP2010505796A (en) 2010-02-25
US20170128423A1 (en) 2017-05-11
HUE027399T2 (en) 2016-09-28
EP2420232A3 (en) 2012-05-02
JP5425631B2 (en) 2014-02-26
EP2420233B1 (en) 2016-01-13
CA2665435C (en) 2016-03-29
ES2425482T3 (en) 2013-10-15
EP2420231B1 (en) 2016-01-13
CN114344293A (en) 2022-04-15
US10357479B2 (en) 2019-07-23
ES2567041T3 (en) 2016-04-19
SI2086535T1 (en) 2013-09-30
DK2086535T3 (en) 2013-07-22
EP2420231A2 (en) 2012-02-22
CL2012001349A1 (en) 2012-10-12
CY2013037I1 (en) 2015-11-04
JP5899165B2 (en) 2016-04-06
CL2007002897A1 (en) 2008-03-07
JP2013216708A (en) 2013-10-24
US9585873B2 (en) 2017-03-07
NZ609533A (en) 2014-08-29
PT2086535E (en) 2013-08-22
EP1908469A1 (en) 2008-04-09
BR122013019533A2 (en) 2015-07-14
EP2420233A2 (en) 2012-02-22
MX360150B (en) 2018-10-24
TWI415605B (en) 2013-11-21
MX360147B (en) 2018-10-24
TWI539949B (en) 2016-07-01
DK2420232T3 (en) 2016-03-07
TW200831078A (en) 2008-08-01
CA2665435A1 (en) 2008-04-10
KR101456151B1 (en) 2014-11-04
EP2420232A2 (en) 2012-02-22
EP2420231A3 (en) 2012-04-11
US20130190373A1 (en) 2013-07-25
CO6180425A2 (en) 2010-07-19
CN101522191A (en) 2009-09-02
BR122013019534A2 (en) 2015-07-14
BRPI0718041A2 (en) 2015-05-12
DK2420231T3 (en) 2016-04-11

Similar Documents

Publication Publication Date Title
EP2420233A3 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
PL1984357T3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
WO2007022506A3 (en) Methods and compositions for treating neurological disease
IL177937A0 (en) 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
IL185422A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
WO2007133622A3 (en) Selective inhibitors of rock protein kinase and uses thereof
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
WO2007115975A3 (en) USE OF kappa OPIOID RECEPTOR ANTAGONIST-CONTAINING COMPOSITIONS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
WO2005082070A3 (en) Compositions and methods for the systemic treatment of arthritis
WO2008087329A3 (en) New drug for treating gastric cancer
WO2007104933A8 (en) Chemical compounds
WO2006136454A3 (en) Use of inhibitors of n-methyl transferases for the therapy of parkinson&#39;s disease
WO2006032994A3 (en) Muscarinic receptor antagonists
WO2007007281A3 (en) Muscarinic receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780037494.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07820908

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002340

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2148/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2665435

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009530883

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09035442

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007304216

Country of ref document: AU

Ref document number: 576109

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020097009113

Country of ref document: KR

Ref document number: 2007820908

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007304216

Country of ref document: AU

Date of ref document: 20071004

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0718041

Country of ref document: BR

Free format text: APRESENTE, NO PRAZO DE 60 (SESSENTA) DIAS, NOVAS FOLHAS DE RELATORIO DESCRITIVO, QUE SE ENCONTRAM FORA DE ORDEM E SEM SENTIDO, COM O TEXTO TRADUZIDO PARA O PORTUGUES, ADAPTADO A NORMA VIGENTE, CONFORME DETERMINA O ART. 7O DA RESOLUCAO INPI PR NO 77/2013 DE 18/03/2013.

ENP Entry into the national phase

Ref document number: PI0718041

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090406